For postmenopausal women with HR+ breast cancer


If you've been diagnosed with hormone receptor-positive (HR+) early breast cancer, you and your doctor may be discussing treatment options for reducing the risk of breast cancer recurrence.

ARIMIDEX is a prescription medicine approved as an adjuvant treatment for postmenopausal women with hormone receptor-positive early breast cancer. ARIMIDEX is also approved for the initial treatment of postmenopausal women with hormone-receptor positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. ARIMIDEX 1 mg is a hormonal treatment that helps fight breast cancer by lowering the amount of the hormone estrogen in the body.

The site you are about to visit is maintained by a third party, who is solely responsible for its contents. AstraZeneca provides this link as a service to Web site visitors. AstraZeneca is not responsible for the privacy policy of any third-party Web sites. We encourage you to read the privacy policy of every Web site you visit. Click CANCEL to return or OK to continue.